Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-263 · 3 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| Arm A (ABT-263 and Ketoconozole) | EXPERIMENTAL | - |
| docetaxel +ABT-263 | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | EXPERIMENTAL | - |
| 6 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ABT-263 | DRUG | Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole. |
| Ketoconazole | DRUG | Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole. |
| Docetaxel | DRUG | 75 mg/m2 will be given by intravenous infusion on day 1 of each 21 -day cycle. 30 mg/m2 will be given by intravenous infusion on day 1, 8, 15 of each 28 -day cycle. |
Inclusion Criteria: * 18 years of age or older. * Has a non-hematologic malignancy (radiographic, histologic, or cytologic confirmation), or hematologic malignancy (histologic or cytologic confirmation) that is either: relapsed or refractory to standard therapy, failed at least one prior therapy or...
ABT-263 is an investigational small molecule developed by Abbott Laboratories for oncology. It has been studied in chronic lymphocytic leukemia, lymphoma, and solid tumors. It is a Phase 1 agent and has not been approved by the FDA. Trials of ABT-263 have been completed, including studies in the United States, Netherlands, and United Kingdom.
ABT-263 has been studied for the treatment of chronic lymphocytic leukemia, lymphoma, and solid tumors. It is an investigational therapy and is not approved for any indication. Clinical trials of ABT-263 enrolled adults aged 18 years and older, including patients with leukemia, lymphoma, and solid tumor diagnoses.
ABT-263 is developed by Abbott Laboratories, which trades under the ticker ABT. Abbott conducted Phase 1 clinical trials of ABT-263 in chronic lymphocytic leukemia, lymphoma, and solid tumors. The program includes completed studies evaluating drug metabolism, combination therapy, and oral bioavailability.
ABT-263 is in Phase 1 clinical development. It is an investigational small molecule and is not FDA approved. The Phase 1 trials of ABT-263 have been completed, including studies assessing ketoconazole effects on metabolism, combination with docetaxel, and oral bioavailability of new formulations.
ABT-263 has been evaluated in completed Phase 1 trials including NCT01021358, which assessed ketoconazole effects on ABT-263 metabolism in lymphoma, chronic lymphocytic leukemia, and solid tumors; NCT00888108, which studied ABT-263 with docetaxel in solid tumors; and NCT00743028, which assessed oral bioavailability of new ABT-263 formulations.
Yes, ABT-263 is also known as navitoclax. Both names refer to the same investigational small molecule developed by Abbott Laboratories. Navitoclax has been studied in Phase 1 trials for chronic lymphocytic leukemia, lymphoma, and solid tumors, including NCT01021358, which used the ABT-263 name in its title.